



Genetic Analysis: Launch of GA-map® Discovery – A microbiome profiling offering for Research Customers

OSLO, NORWAY – 24 October 2023: Microbiome DX company Genetic Analysis AS (“GA” or “the Company”) announces today that the Company launches the GA-map® Discovery – a new microbiome profiling service offering directed to research customers in the academia and microbiome industry. The GA-map® Discovery is GA’s first dedicated offering in the research market which is currently witnessing considerable growth – cementing GA’s position as a pioneer in microbiome disease diagnostics.

Built on the standardized GA-map® platform, GA-map® Discovery is a comprehensive end-to-end microbiota research service for gut and oral microbiota profiling. Comprising more than 170 bacteria markers, the GA-map® Discovery was developed to facilitate the discovery of new biomarkers and bacteria signatures associated with health and disease. GA-map® Discovery is a perfect choice for comparative studies of different disease cohorts, treatment responses, and more. The launch of GA-map® Discovery brings to the market a research service with high accuracy, exceptional reproducibility, and short turnaround time, enabling cost-effective microbiota measurements.

The GA-map® Discovery is GA’s first dedicated offering in the research market. In recent years, microbiome research has witnessed considerable growth, fuelling new inventions in disease diagnostics, treatment selection and monitoring, and disease prevention. The research market for microbiome measurement was valued at \$859 million in 2021 and is projected to reach \$3,417 million by 2031 ⁽¹⁾.

Ronny Hermansen, CEO of Genetic Analysis, comments:

“We are excited to announce our complete offering to this fast-growing research market; the GA-map Discovery, underlines GA’s innovative position in the microbiome space. GA has developed this broad panel of markers to facilitate the needs of academia and industry in their microbiome research. I am proud of our ability to deliver this product as it highlights our team’s dedication to pioneering microbiome diagnostics.”

(1) <https://www.alliedmarketresearch.com/microbiome-sequencing-market-A13576>

For more information, please contact:

Ronny Hermansen, CEO

E-mail: rh@genetic-analysis.com

About Genetic Analysis:

Genetic Analysis AS (GA) is a science-based diagnostic company and pioneer in the human microbiome field with more than 15 years of expertise in research and product development. The unique GA-map® platform is based on a pre-determined multiplex targets approach specialized for simultaneous analysis of a large number of bacteria in one reaction. The test results are generated by utilizing the clinically validated cutting edge GA-map® software algorithm. This enables immediate results without the need for further bioinformatics work. GA’s vision is to become the leading company for standardized gut microbiota testing worldwide, and GA is committed to help unlocking and restoring the human microbiome through its state-of-the-art technology. GA employs a team of highly qualified employees with scientific backgrounds and competence in sales, operations, bioinformatics, molecular biology, and bioengineering.

For more general information: www.genetic-analysis.com

Stay updated on GA and sign up for more investor-related information: <https://www.genetic-analysis.com/subscriptions/>

Interested in reading more about GA's products? Please visit ga-map.com